10 IPOs brought in $1.3 billion this past week, along with 3 SPACs raising $540 million. With a flood of biotechs, most of the IPOs this week had heavy insider buying, and no revenue. They traded very well, however, averaging a 27% gain. The week's worst IPO...read more
Aptinyx, which is developing novel small molecule therapeutics for neurological disorders, raised $102 million by offering 6.4 million shares at $16, the high end of the range of $14 to $16. The company originally planned to offer 5.3 million shares. Existing...read more
Helped by a strong market, the steady stream of June IPOs should continue in the week ahead with eleven companies scheduled to raise a combined $1.4 billion. SMB payments processor i3 Verticals and triple net lease REIT Essential Properties headline the week,...read more
Aptinyx, which is developing therapeutics for neurological disorders, announced terms for its IPO on Monday. The Evanston, IL-based company plans to raise $80 million by offering 5.3 million shares at a price range of $14 to $16. Insiders intend to purchase...read more
US IPO Weekly Recap: Biotechs boom in a 13-deal torrent
10 IPOs brought in $1.3 billion this past week, along with 3 SPACs raising $540 million. With a flood of biotechs, most of the IPOs this week had heavy insider buying, and no revenue. They traded very well, however, averaging a 27% gain. The week's worst IPO...read more
Neurological disorder biotech Aptinyx prices upsized IPO at $16, the high end of the range
Aptinyx, which is developing novel small molecule therapeutics for neurological disorders, raised $102 million by offering 6.4 million shares at $16, the high end of the range of $14 to $16. The company originally planned to offer 5.3 million shares. Existing...read more
US IPO Week Ahead: Health care deals lead 11-IPO week
Helped by a strong market, the steady stream of June IPOs should continue in the week ahead with eleven companies scheduled to raise a combined $1.4 billion. SMB payments processor i3 Verticals and triple net lease REIT Essential Properties headline the week,...read more
Neurological disorder biotech Aptinyx sets terms for $80 million IPO
Aptinyx, which is developing therapeutics for neurological disorders, announced terms for its IPO on Monday. The Evanston, IL-based company plans to raise $80 million by offering 5.3 million shares at a price range of $14 to $16. Insiders intend to purchase...read more